Overview

“Jason is a strong lawyer who doesn’t bring drama to a deal and is good to work with. He is level-headed, thoughtful and smart.” – Benesch client, Chambers USA

Jason regularly represents a variety of dialysis and nephrology providers, dialysis vascular access centers, office-based laboratories, cardiac catheterization laboratories, ambulatory surgery centers, physician group practices, academic medical centers, post-acute care facilities, laboratory companies, healthcare information technology companies and other healthcare providers in structuring mergers and acquisitions, joint ventures, accountable care and capitated care arrangements and syndications implicating various regulatory compliance issues commonly associated with such transactions.

Jason regularly provides guidance on physician self-referral prohibitions and anti-kickback issues, the corporate practice of medicine and MSO-friendly PC structures, fee splitting, false claims act matters, licensing, changes of ownership and control, acquiring certificates of need, physician employment and recruitment, compliance with The Joint Commission and other accreditation standards, hospital and medical staff bylaws and other regulatory compliance issues.

Jason regularly speaks at a variety of industry trade group events hosted by the Renal Physicians Association (RPA), the American Society of Diagnostic and Interventional Nephrology (ASDIN), the Vascular Access Society of the Americas (VASA) and the Outpatient Endovascular and Interventional Society (OEIS).  Jason serves as co-counsel for the RPA and OEIS and serves on VASA’s audit committee.  Jason has consistently been recognized as a leading lawyer by Chambers USA and he is a former President of the Illinois Association of Healthcare Attorneys where he also served as a member of its board of directors for many years. Jason has also served as the editor-in-chief of Health Care Law Monthly, a LexisNexis publication.

Featured endorsements

Experience

Credentials

Education

Emory University, 1998, B.A.
  • Phi Beta Kappa
DePaul University College of Law, 2005, J.D., cum laude

Bar & Court Admissions

Illinois

More

  • Past President and various officer and board positions, Illinois Association of Healthcare Attorneys (2011-2016)
  • Member, Illinois Association of Healthcare Attorneys (2005-present)
  • Member, American Health Lawyers Association (2005-present)
  • Board Member, Chicago End-of-Life Care Coalition, 2007-2011
  • Board Member, Chicago Bar Association, 2007-2011
  • Listed, Chambers USA Band 2, Healthcare, 2026
  • Listed, Legal 500 US Elite: Corporate & M&A list
  • Named “Leading Lawyer,” Law Bulletin Media, 2022
  • Listed, The Best Lawyers in America®, Health Care Law, 2021-2026
  • Listed, Chambers USA Leading Lawyers, Healthcare, 2019-2025
  • Selected for inclusion in America’s Leading Lawyers for Business, Healthcare, Illinois, Chambers USA, 2019
  • Named an “Emerging Lawyer,” Health Law, Leading Lawyers, 2015
  • Selected as a “Trusted Expert,” LTACH Law, Acute Long Term Hospital Association, Washington Report, 2009

Related News & Insights

Client Alerts & Insights 5.21.26

The LEAD Model—Kidney Care’s Value-Based Care Journey LEADs Here

For more than a decade, nephrology practices have participated in Innovation Center kidney‑focused models—beginning with ESRD Seamless Care Organizations (“ESCOs”) under the Comprehensive ESRD Care (“CEC”) Model (2015–2021), followed by today’s Kidney Care Choices (“KCC”) Model (2022–2027). With KCC scheduled to end in December 2027, kidney care providers are approaching a critical transition point. The Long‑term Enhanced ACO Design (“LEAD”) Model, for which CMS released the Request for Applications (“RFA”) on March 31, 2026 (revised April 15, 2026), represents the next phase of CMS’s value‑based care strategy—but it differs fundamentally from the kidney‑specific models that preceded it.